The global Post-Menopausal Osteoporosis Market exhibited remarkable strength in 2021 and is projected to sustain a swift compound annual growth rate (CAGR) in terms of revenue throughout the forecasted period. The escalating prevalence of osteoporosis cases among menopausal women worldwide is propelling the expansion of revenues within the post-menopausal osteoporosis treatment market. However, this growth trajectory encounters hindrances stemming from a dearth of proficient experts and the adverse effects linked with treatment choices for post-menopausal osteoporosis.
Osteoporosis, characterized by reduced bone mineral density (BMD) and the resulting fragility of bones due to the degradation of microstructural bone tissue, has emerged as a multifaceted systemic skeletal ailment. The World Health Organization (WHO) identifies osteoporosis as a condition wherein the T-score is equal to or less than 2.5, and osteopenia is identified by a T-score ranging from 1.0 to 2.5. The anatomical areas of focus for diagnosis are the lumbar spine and femoral neck.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5519
Market Growth Catalysts: Driving Factors - Numerous drivers are fostering the growth of revenues within the post-menopausal osteoporosis market. As estimated, the prevalence of osteoporosis escalates from approximately one-third in individuals aged 50 to 60, to over 50% among those aged 80 and above. By 2050, approximately 6 million individuals globally will suffer from osteoporosis, encompassing both genders. Notably, 75% of these cases will be concentrated in developing nations. The availability of FDA-approved non-estrogen treatment alternatives, including bisphosphonates and denosumab, is fueling the expansion of the post-menopausal osteoporosis treatment market. Moreover, the burgeoning population of elderly women around the world is contributing to the growth, with approximately 9.31 million women in the US aged 50 and above exhibiting menopausal symptoms, representing 36.8% of all females. Capitalizing on this trend, advancements in treatment modalities, such as injectable options and vitamin supplements, designed for the alleviation of post-menopausal osteoporosis symptoms, are further elevating market revenues.
Inhibiting Factors - The treatment landscape for post-menopausal osteoporosis is hampered by several deterrents. The availability of numerous physical therapies in the market for treating post-menopausal osteoporosis is casting a negative influence on the treatment market. Additionally, the prolonged usage of estrogen is linked to endometrial cancer, impacting the acceptance of hormone replacement therapy. This therapy is associated with a spectrum of side effects. Chinese menopause guidelines recommend hormone therapy for women below the age of 60, who are at risk of osteoporotic fractures; however, for fracture prevention alone, the therapy is not advised for women aged over 60. The risks associated with this therapy increase with higher doses and prolonged usage. Such factors are curtailing the growth of revenue in the post-menopausal osteoporosis treatment market.
Opportunities: The escalating research and development endeavors focused on pharmaceutical treatments tailored for post-menopausal osteoporosis are instrumental in fostering revenue growth in the market. Novel non-estrogen modulator medications are under development for osteoporosis treatment. Educating and raising awareness among the population about this condition can be leveraged as an opportunity by scientists and innovators to devise effective medications for post-menopausal osteoporosis patients, thereby sustaining revenue growth.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5519
Geographic Market Dynamics: Dominant Revenue Share - North America is anticipated to secure the largest share of revenue during the forecast period. This dominance can be attributed to the introduction of new treatment options in the region. Additionally, increased healthcare expenditures and the accessibility of diverse treatment choices are contributing to the market's revenue growth. A heightened awareness about the disease is also playing a role in augmenting revenues. Notably, the challenges associated with hormone replacement therapy, as outlined in Chinese menopause guidelines, contribute to this growth trajectory.
Swiftly Expanding Region - Asia Pacific is poised to register a notable revenue CAGR over the forecast period. Countries such as China and India are witnessing a substantial rise in the incidence of post-menopausal osteoporosis. The presence of targeted drug manufacturers in the region, along with the expansion of healthcare infrastructure, is propelling revenue growth. These factors collectively indicate a positive growth trajectory for the market in Asia Pacific.
Key Trends and Innovations: Since March 2022, a comparative study has been underway to evaluate the efficacy of Ramucirumab and Denosumab, two FDA-approved medications, in treating osteoporosis. Moreover, a randomized multicenter phase III study is currently ongoing to compare the effectiveness and safety of RGB-14-P to Prolia in women with post-menopausal osteoporosis.
Competitive Landscape and Strategies: Organic and inorganic strategies are being employed in the market. For instance, as of August 2022, Pre-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients with Postmenopausal Osteoporosis is being conducted. In April 2019, Evenity gained FDA approval to treat osteoporosis in postmenopausal women at high risk of fractures.
Key Market Players: Prominent companies in the market include Amgen Inc., Clonz Biotech, Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated, Merck Co., Inc., Outlook Therapeutics, Inc., and Paras Biopharmaceuticals.
In Conclusion: The provided report furnishes historical data, forecasts, and revenue growth projections globally, regionally, and on a country level. It delves into analysis, industry trends, and consumption patterns for various regions, major countries, and segments from 2019 to 2030. The report encompasses industry analysis, a competitive landscape, company financials, and impact analysis. It outlines key segments such as end-use outlook, distribution channel outlook, route of administration outlook, and treatment outlook. Furthermore, regional outlooks for North America, Europe, Asia Pacific, Latin America, and the Middle East Africa are included, highlighting revenue projections and trends in each region.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5519
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Adalimumab, Infliximab and Etanercept Biosimilars Market
Capillary Blood Collection Market
Laser Fiber in Medical Applications Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
